Quick Answer
BriaCell Therapeutics Corp. reported Diluted EPS of $62.19 per share (loss) for fiscal year 2025.
BriaCell Therapeutics Corp. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$62.19 | -42.4% |
| 2024 | -$43.68 | -3260.0% |
| 2023 | -$1.30 | +24.9% |
| 2022 | -$1.73 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| October 31, 2025 | -$4.35 | +86.7% | -165.2% |
| April 30, 2025 | -$1.64 | -201.9% | +29.6% |
| January 31, 2025 | -$2.33 | +78.1% | +92.9% |
| October 31, 2024 | -$32.67 | -6434.0% | -2129.2% |
| April 30, 2024 | $1.61 | +603.1% | +115.1% |
| January 31, 2024 | -$10.64 | -1281.8% | -2028.0% |
| October 31, 2023 | -$0.50 | -614.3% | -56.2% |
| April 30, 2023 | -$0.32 | +50.8% | +58.4% |
- BriaCell Therapeutics Corp. showed a decrease of -42.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, BriaCell Therapeutics Corp.’s diluted eps has declined by 3494.8% (from $1.73 per share (loss) to $62.19 per share (loss)).
- The most recent figure is from BriaCell Therapeutics Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on October 16, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: